Endocrine Abstracts

Bone loss is a frequent complication of aromatase inhibitors (AIs) therapy in women with breast cancer. Bone-active drugs are effective in protecting the skeleton from detrimental actions of AIs. However, bone mineral density (BMD) was the primary end-point in most of published studies, whereas data on fractures were scant and mainly limited to denosumab. In this prospective study, we investigated the effects of denosumab, oral bisphosphonates and intravenous zoledronate on ri...

Background: Cushing’s syndrome (CS) is associated with high morbidity and presents high interindividual variability. Easily measurable biomarkers, in addition to the hormone assays currently used for diagnosis, could better quantify the individual biological impact of glucocorticoids. The aim of this study is to identify such biomarkers through the analysis of whole blood transcriptome.Methods: Whole blood transcriptome was evaluated in 57 samples (...

An initial multi-omics analysis of PitNETs has refined histological classifications, and could improve diagnostic and prognostic assessment (Neou, Cancer Cell 2020). Of all omics, transcriptome best discriminates between these different classes. This molecular classification has been built upon frozen samples, which are difficult to use in routine clinical practice.Aim: Demonstrate the feasibility of measuring the transcriptome in Formalin-Fixed Paraffin...

Management of skeletal fragility in women with early breast cancer (BC) under hormone-deprivation therapies (HDTs) may be a challenge and it is still unknown whether anti-osteoporotic therapies could be active in preventing fractures in pre-menopausal women exposed to HDTs. In this real-world, multicenter study, we evaluated the effectiveness of bone-active drmgs and determinants of vertebral fractures (VFs) in 306 pre-menopausal women (mean age 47.15±5.09, range: 30-54) wi...